- Home
- NCLH vs MRNA Comparison
NCLH vs MRNA Comparison
Compare NCLH & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCLH | MRNA |
|---|---|---|
| Founded | 1966 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 11.5B |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NCLH | MRNA |
|---|---|---|
| Price | $22.72 | $31.14 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 18 | 13 |
| Target Price | $28.11 | ★ $33.25 |
| AVG Volume (30 Days) | ★ 17.1M | 10.4M |
| Earning Date | 11-04-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $9,692,558,000.00 | $2,232,000,000.00 |
| Revenue This Year | $6.85 | N/A |
| Revenue Next Year | $10.76 | $2.17 |
| P/E Ratio | $16.58 | ★ N/A |
| Revenue Growth | ★ 3.59 | N/A |
| 52 Week Low | $14.21 | $22.28 |
| 52 Week High | $29.29 | $48.92 |
Technical Indicators
Market Signals| Indicator | NCLH | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 63.64 | 58.27 |
| Support Level | $21.51 | $32.14 |
| Resistance Level | $24.32 | $35.90 |
| Average True Range (ATR) | 0.87 | 1.59 |
| MACD | 0.38 | 0.27 |
| Stochastic Oscillator | 73.49 | 46.75 |
Price Performance
Historical ComparisonAbout NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 38,400 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.